The PARTNERS Trial Is Running a Clinical Experiment That Has Never Been Done Before. The World Is Watching.
The PARTNERS trial opened BVD enrollment July 2, 2026, testing MBP134 and obeldesivir for a hemorrhagic fever that kills...
Your AI Scored 92% on the Medical Exam. That Number Is Lying to You.
Health AI acing benchmarks while failing real clinical tasks exposes a validation gap that trial sponsors and the FDA...
Benchmark Scores Don’t Break. Clinical Reality Does. The Health AI Readiness Illusion.
Nature Medicine's frontier AI evaluation exposes a dangerous gap: models acing medical benchmarks collapse under adversarial pressure, and the...
What the MASAI Trial Correspondence in The Lancet Actually Says About AI Screening Evidence
The Lancet correspondence on the MASAI trial exposes a core evidentiary gap: AI mammography's performance gains rest on intermediate...
Obesity Trials Are Optimized to Win Approval, Not to Predict Real-World Use
Nature Medicine's 2026 analysis exposes why obesity drug trials maximizing weight loss endpoints produce results that collapse on contact...
Nature Medicine’s June 2026 Benchmark Study Reveals General-Purpose LLMs Outperform FDA-Cleared Clinical AI — and Exposes a Validation Gap Regulators Have Not Closed
A Nature Medicine study finds GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools on...
An Open Letter to Acting Commissioner Diamantas: The FDA Needs a Regulatory Pathway for Vaccine-Based Dementia Prevention Trials Now
Nature Medicine just made the case for large-scale RCTs of live-attenuated shingles vaccination for dementia prevention. Acting Commissioner Diamantas,...
Adaptive DBS Just Rewrote the Rules for CNS Trial Design — Is the FDA Ready?
A Nature Medicine randomized trial shows adaptive DBS cuts gait variability in Parkinson's. The real story is what its...
What the PRAC’s June 2026 Valproate Meeting Highlights Actually Say About Paternal Exposure Risk
EMA's PRAC found paternal valproate exposure evidence "inconsistent" with causal NDD risk in offspring — but still recommended precautionary...
Spatial CRISPR Screening Just Made Your Preclinical Models Look Like Guesswork
Nature Biotechnology's Perturb-DBiT maps CRISPR perturbations in native tissue — and exposes why dissociated-cell screens keep producing trials that...